Sun Wen, Yan Yang, Hu Shidong, Liu Boyan, Wang Shuying, Yu Wenli, Li Songyan
The First Central Clinical School, Tianjin Medical University, Tianjin, China.
Department of Anesthesiology, the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Ann Transl Med. 2022 Feb;10(4):219. doi: 10.21037/atm-22-477.
Patients in the intensive care unit (ICU) are often under stress and fail to cooperate well with invasive treatments. Analgesia and sedation are of great significance for reducing the suffering of patients and ensuring the application and effectiveness of treatment. For better clinical choice, we aimed to explore the effect of the combination of propofol + fentanyl or midazolam + fentanyl on the short-term prognosis of hospitalized patients in the ICU.
According to the inclusion and exclusion criteria, we retrospectively included patients in the MIMIC-IV database receiving midazolam + fentanyl or propofol + fentanyl analgesic and sedative treatment using Structured Query Language (SQL) to extract clinical data from the MIMIC-IV database. The primary endpoint was the death rate within 28 days after the patient was admitted to the ICU. Doubly robust estimation was used to infer the relationship between sedation and analgesia and 28 days outcome. The gradient boosted model (GBM) was used to estimate the propensity score (PS) of the patient's sedation and analgesia program, PS was used as the weight, and the inverse probabilities weighting (IPW) model was used to generate a weighted cohort.
In total, 4,188 cases were included, with 2,174 (51.9%) in the propofol group and 2,014 (48.1%) in the midazolam group. In the PS score matching cohort, the 28-day mortality of patients in the midazolam group was 30.8%, and the 28-day mortality of patients in the propofol group was 25.5%. The adjusted odds ratio (OR) value was 1.421 [95% confidence interval (CI): 1.118-1.806, P<0.001]. Patients in the propofol group did not use vasoactive drugs for a longer period of time than the midazolam group, and patients in the propofol group received significantly more fluids than those in the midazolam group in the first three days after admission to the ICU.
Compared with midazolam combined with fentanyl, propofol combined with fentanyl for sedation and analgesia can reduce the risk of short-term death in ICU patients.
重症监护病房(ICU)患者常处于应激状态,难以很好地配合侵入性治疗。镇痛和镇静对于减轻患者痛苦、确保治疗的实施及有效性具有重要意义。为了做出更好的临床选择,我们旨在探讨丙泊酚+芬太尼或咪达唑仑+芬太尼联合使用对ICU住院患者短期预后的影响。
根据纳入和排除标准,我们回顾性纳入了MIMIC-IV数据库中接受咪达唑仑+芬太尼或丙泊酚+芬太尼镇痛镇静治疗的患者,使用结构化查询语言(SQL)从MIMIC-IV数据库中提取临床数据。主要终点是患者入住ICU后28天内的死亡率。采用双重稳健估计来推断镇静镇痛与28天结局之间的关系。使用梯度提升模型(GBM)估计患者镇静镇痛方案的倾向评分(PS),将PS用作权重,并使用逆概率加权(IPW)模型生成加权队列。
共纳入4188例病例,丙泊酚组2174例(51.9%),咪达唑仑组2014例(48.1%)。在PS评分匹配队列中,咪达唑仑组患者的28天死亡率为30.8%,丙泊酚组患者的28天死亡率为25.5%。调整后的比值比(OR)值为1.421[95%置信区间(CI):1.118 - 1.806,P<0.001]。丙泊酚组患者使用血管活性药物的时间比咪达唑仑组更长,且在入住ICU后的前三天,丙泊酚组患者接受的液体量显著多于咪达唑仑组。
与咪达唑仑联合芬太尼相比,丙泊酚联合芬太尼用于镇静镇痛可降低ICU患者短期死亡风险。